Table 3.

Examples of drug combinations used in metronomic chemotherapy regimens

MCTh regimen	Clinical phase	Indication	Significant results	Reference
Oral vinorelbine 50 mg three times weekly	Phase 2	Stage IIIB–IV NSCLC	Treatment was well tolerated with rare serious toxicity	[77]
Capecitabine 625 mg/m2/d BD for 3 weeks plus bevacizumab 7.5 mg/kg i.v. every 3 weeks	Phase 2	mCRC	PFS duration was longer in treatment group. However, benefits not seen once bevacizumab is withdrawn	[76]
Thalidomide 3 mg/kg OD, Celecoxib 100 mg BD for patients <20 kg 200 mg BD for patients 20–50 kg 400 mg BD for patients >50 kg	Phase 3	Refractory/progressive non-hematopoietic extracranial solid tumors following treatment with at least 2 lines of chemotherapy	Longer PFS seen only in patients without bone sarcomas (post hoc analysis) and those able to tolerate more than 3 cycles (9 weeks) benefit	[82]

OD: Once daily, BD: Twice daily, PFS: Progression-free survival, NSCLC: Nonsmall-cell lung carcinoma, mCRC: Metastatic colorectal carcinoma, TNBC: Triplenegative b breast cancer, DFS: Disease-free survival, OS: Overall survival, MCTh: Metronomic chemotherapy